Actinium Pharmaceuticals Inc. (Delaware)

5.41-0.0600-1.10%Vol 46.99K1Y Perf -21.07%
Aug 9th, 2022 16:00 DELAYED
BID5.40 ASK5.46
Open5.40 Previous Close5.47
Pre-Market- After-Market5.44
 - -  0.03 0.55%
Target Price
31.67 
Analyst Rating
Strong Buy 1.00
Potential %
485.40 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★     57.01
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
16.98 
Earnings Rating
Strong Buy
Market Cap128.67M 
Earnings Date
12th Aug 2022
Alpha-0.01 Standard Deviation0.23
Beta0.37 

Today's Price Range

5.395.55

52W Range

4.4110.30

5 Year PE Ratio Range

-2.70-2.10

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
9.84%
1 Month
4.79%
3 Months
-0.91%
6 Months
1.86%
1 Year
-21.07%
3 Years
-20.03%
5 Years
-69.61%
10 Years
-

TickerPriceChg.Chg.%
ATNM5.41-0.0600-1.10
AAPL164.920.05000.03
GOOG117.50-0.6400-0.54
MSFT282.301.98000.71
XOM90.591.64001.84
WFC43.400.21000.49
JNJ170.18-0.0200-0.01
FB196.640.99000.51
GE74.93-0.2500-0.33
JPM115.381.03000.90
 
ProfitabilityValueIndustryS&P 500US Markets
-
-1 693.30
-1 656.60
-
-
RevenueValueIndustryS&P 500US Markets
1.20M
0.05
-
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.31-0.2325.81
Q03 2021-0.29-0.30-3.45
Q02 2021-0.30-0.2516.67
Q01 2021-0.35-0.2917.14
Q03 2019-1.20-1.200.00
Q02 2019--0.90-
Q01 2019-1.80-1.5016.67
Q04 2018-0.06-0.060.00
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.2328.13Positive
9/2022 QR-0.2528.57Positive
12/2022 FY-1.0722.46Positive
12/2023 FY-1.228.96Positive
Next Report Date12th Aug 2022
Estimated EPS Next Report-0.23
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume46.99K
Shares Outstanding23.78K
Shares Float23.78M
Trades Count397
Dollar Volume255.91K
Avg. Volume128.82K
Avg. Weekly Volume129.85K
Avg. Monthly Volume93.29K
Avg. Quarterly Volume163.33K

Actinium Pharmaceuticals Inc. (Delaware) (AMEX: ATNM) stock closed at 5.47 per share at the end of the most recent trading day (a -4.54% change compared to the prior day closing price) with a volume of 140.26K shares and market capitalization of 128.67M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 25 people. Actinium Pharmaceuticals Inc. (Delaware) CEO is Sandesh Seth.

The one-year performance of Actinium Pharmaceuticals Inc. (Delaware) stock is -21.07%, while year-to-date (YTD) performance is -8.99%. ATNM stock has a five-year performance of -69.61%. Its 52-week range is between 4.41 and 10.3, which gives ATNM stock a 52-week price range ratio of 16.98%

Actinium Pharmaceuticals Inc. (Delaware) currently has a PE ratio of -4.40, a price-to-book (PB) ratio of 1.74, a price-to-sale (PS) ratio of 99.23, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -33.80%, a ROC of -35.26% and a ROE of -36.25%. The company’s profit margin is -%, its EBITDA margin is -1 656.60%, and its revenue ttm is $1.20 Million , which makes it $0.05 revenue per share.

Of the last four earnings reports from Actinium Pharmaceuticals Inc. (Delaware), there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.23 for the next earnings report. Actinium Pharmaceuticals Inc. (Delaware)’s next earnings report date is 12th Aug 2022.

The consensus rating of Wall Street analysts for Actinium Pharmaceuticals Inc. (Delaware) is Strong Buy (1), with a target price of $31.67, which is +485.40% compared to the current price. The earnings rating for Actinium Pharmaceuticals Inc. (Delaware) stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Actinium Pharmaceuticals Inc. (Delaware) has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Actinium Pharmaceuticals Inc. (Delaware) has a Buy technical analysis rating based on Technical Indicators (ADX : 24.05, ATR14 : 0.28, CCI20 : 172.66, Chaikin Money Flow : 0.00, MACD : 0.07, Money Flow Index : 62.29, ROC : 7.25, RSI : 42.78, STOCH (14,3) : 73.27, STOCH RSI : 0.82, UO : 55.78, Williams %R : -26.73), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Actinium Pharmaceuticals Inc. (Delaware) in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its most advanced products are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

CEO: Sandesh Seth

Telephone: +1 646 677-3870

Address: 275 Madison Avenue, New York 10016, NY, US

Number of employees: 25

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

69%31%

Bearish Bullish

74%26%

Bearish Bullish

63%37%

TipRanks News for ATNM

Wed, 27 Apr 2022 14:06 GMT Actinium Pharmaceuticals (ATNM) Received its Third Buy in a Row

- TipRanks. All rights reserved.

Tue, 26 Apr 2022 12:43 GMT Actinium Pharmaceuticals (ATNM) Receives a Buy from Alliance Global Partners

- TipRanks. All rights reserved.

Mon, 25 Apr 2022 14:55 GMT Actinium Pharmaceuticals (ATNM) Gets a Buy Rating from H.C. Wainwright

- TipRanks. All rights reserved.

Tue, 12 Apr 2022 15:25 GMT Actinium Pharmaceuticals (ATNM) Receives a Buy from Maxim Group

- TipRanks. All rights reserved.

Tue, 12 Apr 2022 10:12 GMT Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Actinium Pharmaceuticals (ATNM) and Bicycle Therapeutics (BCYC)

- TipRanks. All rights reserved.

News

Stocktwits